实体瘤疗效评价标准(RECIST)v1.1 非靶病灶评估的要点与陷阱
本文以图文述评形式回顾 RECIST v1.1 指南中非靶病灶的评估规则,指出非靶病灶相关规则定义不够明确且带有一定主观性,并展示基线和随访疗效评估中常见的非靶病灶判读错误。
要点
- RECIST v1.1 将肿瘤病灶分为靶病灶和非靶病灶,非靶病灶的评估规则定义不够明确且带有一定主观性。
- 非靶病灶评估错误可发生在基线评估和随访疗效评估两个环节。
- 本文以图文述评形式回顾 RECIST v1.1 指南并展示常见非靶病灶判读错误。
核心结论
- 非靶病灶的 RECIST v1.1 评估规则定义不够明确且带有一定主观性,基线和随访评估中均可出现判读错误。
研究设计与样本
- 图文述评(pictorial essay),回顾 RECIST v1.1 指南并展示基线和随访疗效评估中常见的非靶病灶错误。
诊断标准与关键数值
- RECIST v1.1 将肿瘤部位分为靶病灶和非靶病灶。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Oncologic imaging is an important facet of abdominal imaging that radiologists encounter nearly every day. Many oncology clinical trials utilize response evaluation criteria in solid tumors (RECIST) version 1.1 which divides tumor sites into target and non-target lesions. Although RECIST v1.1 provides clear instructions regarding the use of imaging in clinical trials, errors in response assessment still occur using these criteria. This is especially true of response assessment with regards to non-target lesions which involve rules which are less well-defined and somewhat subjective. This pictorial essay will review RECIST v1.1 guidelines and common non-target lesion errors which can occur at baseline and follow-up response assessment.
引用
- Morse B, Jeong D, Ihnat G, et al. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1.1 non-target lesion assessment. Abdom Radiol (NY). 2019. PMID: 30196362. doi:10.1007/s00261-018-1752-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。